Astec Lifesciences Ltd (ASTEC) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Astec Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Please find attached Press Release
Press Release · 27 Oct 2026, 12:37 am
Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds Astec LifeSciences reported a 3% YoY decline in Q2FY27 consolidated total income to ₹72.6 crore, alongside a widened EBITDA loss of ₹19.2 crore versus a loss of ₹5.6 crore in Q2FY26. Net loss expanded to ₹37.4 crore from ₹24.4 crore YoY, impacted by subdued demand, lower realizations, elevated input costs, and an inventory write-down of ₹3 crore. Segmentally, enterprise revenue dropped 6% YoY to ₹57.0 crore, while CDMO grew 15% YoY to ₹15.0 crore. Geographically, domestic revenue rose 32% YoY to ₹43.1 crore, offset by a 30% export decline to ₹28.9 crore.
Please find enclosed Financials Results for the Quarter and Half year ended .
Financial Result · 26 Oct 2026, 10:42 pm
Astec LifeSciences Limited has informed the Exchange regarding Outcome of Board Meeting held on October 26, 2026.
Outcome · 26 Oct 2026, 10:26 pm
Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue Astec LifeSciences reported consolidated revenue from operations of ₹7,202.01 lakh for the quarter ended 30th Sep'26, down 2.31% YoY from ₹7,372.06 lakh and 13.81% QoQ from ₹8,356.43 lakh. Consolidated net loss widened significantly to ₹3,739.71 lakh compared to a loss of ₹2,441.70 lakh in Q2 FY26 and ₹1,870.73 lakh in Q1 FY27. Operating margin deteriorated sharply to -27.48% versus -9.07% YoY. Diluted EPS stood at ₹(16.79). Total debt-to-assets remained at 0.42, while net cash generated from operating activities reached ₹12,195.71 lakh for H1 FY27.
Kindly find attached Outcome of Board meeting
Outcome · 26 Oct 2026, 10:23 pm
Astec LifeSciences Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026.
Outcome · 26 Oct 2026, 10:21 pm
Astec Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 7,202 (-2.3% YoY | -13.8% QoQ) ■ EBITDA: -1,979 (-196.0% YoY | -2871.3% QoQ) ■ EBITDA Margin (%): -27.5 (-1841 bps YoY | -2668 bps QoQ) ■ PAT: -3,741 (-53.1% YoY | -99.9% QoQ) ■ EPS (INR): -16.8 (-48.1% YoY | -99.9% QoQ)
ASTEC LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 26 Oct 2026, 5:30 am
Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Please find enclosed intimation.
Intimation · 26 Oct 2026, 5:30 am
Astec LifeSciences Schedules Board Meeting for Q2 and H1 FY27 Results Astec LifeSciences Limited has scheduled a meeting of its Board of Directors on Monday, 26th Oct'26. The board will, inter alia, consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26, following a review by the Audit Committee.
ASTEC LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 26 Oct 2026, 5:30 am
To consider and approve the financial results for the Quarter and Half Year ended September 30, 2026
Intimation · 26 Oct 2026, 5:30 am
Please find enclosed, Company''s response.
Others (Uncategorized) · 01 Oct 2026, 10:15 pm
Astec LifeSciences Clarifies Significant Trading Volume Increase Across Exchanges Astec LifeSciences responded to BSE on 1st Oct'26 regarding the recent significant increase in trading volume across exchanges. The company confirmed compliance with Regulation 30 of SEBI Listing Regulations and PIT Regulations. Management clarified that no undisclosed, price-sensitive events or material corporate developments have occurred that require mandatory disclosure, reiterating its commitment to promptly share all material information with stock exchanges as mandated.
The Exchange has sought clarification from Astec Lifesciences Ltd on October 1, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 01 Oct 2026, 8:40 pm
Please find enclosed, Company''s response.
Others (Uncategorized) · 18 Sept 2026, 9:05 pm
Astec LifeSciences Clarifies Significant Trading Volume Increase Across Exchanges Astec LifeSciences responded to BSE's query on 18th Sep'26 regarding a significant increase in trading volumes across exchanges. The company confirmed it is fully compliant with SEBI (LODR) Regulation 30 and PIT Regulations. It clarified that there are no undisclosed, price-sensitive events or pending material developments requiring disclosure that could impact share price or trading activity.
The Exchange has sought clarification from Astec Lifesciences Ltd on September 18, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 18 Sept 2026, 5:48 pm
Please find enclosed, our response to BSE e-mail dated September 10, 2026.
Others (Uncategorized) · 11 Sept 2026, 3:40 pm
Astec LifeSciences Clarifies Significant Security Trading Volume Increase Astec LifeSciences responded on 11th Sep'26 to BSE’s query regarding recent significant increases in trading volume. The company confirmed full compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements and PIT Regulations. It clarified that there are no undisclosed material events or price-sensitive developments requiring mandatory disclosure, reiterating its commitment to prompt regulatory reporting.
The Exchange has sought clarification from Astec Lifesciences Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 10 Sept 2026, 11:12 pm
Please find enclosed, our response.
Others (Uncategorized) · 09 Sept 2026, 6:22 pm
Astec LifeSciences Clarifies Significant Trading Volume Surge Across Exchanges Responding to BSE's query regarding a significant increase in trading volume on 9th Sep'26, Astec LifeSciences confirmed full compliance with SEBI Listing Regulations (Regulation 30) and PIT Regulations. The company stated that no undisclosed price-sensitive events, material developments, or information requiring regulatory disclosure have occurred that would impact share price or trading activity.
The Exchange has sought clarification from Astec Lifesciences Ltd on September 09, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Others (Uncategorized) · 09 Sept 2026, 5:05 pm
Please find enclosed, AGM proceedings, Scrutinizer''s Report, Annual Report and Voting Results.
Annual General Meeting · 01 Aug 2026, 3:44 am
Please find enclosed, AGM proceedings, Scrutinizer''s Report, Annual Report and Voting Results.
Annual General Meeting · 01 Aug 2026, 3:39 am
Please find enclosed, AGM proceedings, Scrutinizer''s Report, Annual Report and Voting Results.
Annual General Meeting · 01 Aug 2026, 3:34 am
Please find enclosed AGM Proceeding, Scrutinizer Report, Annual Report, Voting Results.
Annual General Meeting · 01 Aug 2026, 3:32 am
Please find attached Press Release dated 31st July 2026
Press Release · 01 Aug 2026, 2:36 am
Astec Q1FY27: EBITDA Breakeven Achieved Despite Revenue Decline Astec LifeSciences reported Q1FY27 results, achieving EBITDA breakeven at ₹0.1 crore versus a ₹10.5 crore loss in Q1FY26. Total income declined 8% YoY to ₹84.3 crore. The net loss narrowed significantly to ₹18.7 crore from a ₹33.0 crore loss. Performance was driven by a favorable product mix and improved margins. Enterprise products revenue grew 42% YoY to ₹51.8 crore, offsetting a 41.8% decline in CDMO revenue. Domestic sales grew 11.3% while exports fell 27.5% YoY.
Please find attached the financial results for the Quarter ended June 30, 2026
Financial Result · 31 Jul 2026, 8:54 pm
Astec LifeSciences Reports Net Loss on Declining Revenue for Q1FY27 Astec LifeSciences reported a consolidated net loss of ₹1,870.73 lakhs for Q1FY27, a significant downturn from a net loss of ₹774.70 lakhs in Q4FY26 and ₹3,302.69 lakhs in Q1FY26. Revenue from operations for the quarter ended 30 Jun'26 stood at ₹8,356.43 lakhs, a 47.3% decline QoQ from ₹15,862.26 lakhs and an 8.2% drop YoY from ₹9,108.21 lakhs. The company's basic EPS was negative at (₹8.40) compared to (₹3.48) in the previous quarter and (₹16.85) in the prior year's quarter.
Please find attached the Outcome of Board Meeting
Outcome · 31 Jul 2026, 8:45 pm
Astec Lifesciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 8,356 (-8.3% YoY | -47.3% QoQ) ■ EBITDA: -66.6 (+93.9% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -0.8 (+1126 bps YoY | Profit to Loss QoQ) ■ PAT: -1,872 (+43.3% YoY | -141.3% QoQ) ■ EPS (INR): -8.40 (+50.1% YoY | -141.4% QoQ)
Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 31 Jul 2026, 5:30 am
Astec LifeSciences to Announce Q1 FY27 Results on 31 Jul'26 Astec LifeSciences has scheduled a Board of Directors meeting on Friday, 31 Jul'26. The primary agenda is to consider and approve the standalone and consolidated unaudited financial results for the first quarter ending 30 Jun'26. The results will be reviewed by the Audit Committee before board approval. This announcement is pursuant to SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.